Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.12M | 7.62M | 3.68M | 3.77M | 2.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.14M | 10.37M | 5.66M | 6.23M | 5.90M |
| Operating Income | -7.14M | -10.37M | -5.66M | -6.23M | -5.90M |
| Income Before Tax | -5.84M | -9.33M | -4.82M | -6.81M | -5.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.84M | -9.33M | -4.82M | -6.81M | -5.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.84M | -9.33M | -4.82M | -6.81M | -5.61M |
| EBIT | -7.14M | -10.37M | -5.66M | -6.23M | -5.90M |
| EBITDA | -7.11M | -10.34M | -5.62M | -6.20M | -5.89M |
| EPS Basic | -0.07 | -0.13 | -0.07 | -0.10 | -0.09 |
| Normalized Basic EPS | -0.05 | -0.08 | -0.04 | -0.06 | -0.05 |
| EPS Diluted | -0.07 | -0.13 | -0.07 | -0.10 | -0.09 |
| Normalized Diluted EPS | -0.05 | -0.08 | -0.04 | -0.06 | -0.05 |
| Average Basic Shares Outstanding | 80.41M | 69.84M | 68.75M | 67.26M | 65.16M |
| Average Diluted Shares Outstanding | 80.41M | 69.84M | 68.75M | 67.26M | 65.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
